At 'PRESENT,' Galena still blinded to data as operational review of Neuvax trial underway

Officials at Galena Biopharma Inc. are still in the dark on data from the phase III PRESENT trial of cancer vaccine Neuvax, company president and CEO Mark Schwartz revealed Friday on a conference call with analysts.